Targeted Delivery of Tumor Antigens to Activated Dendritic Cells via CD11c Molecules Induces Potent Antitumor Immunity in Mice
- 15 July 2009
- journal article
- Published by American Association for Cancer Research (AACR) in Clinical Cancer Research
- Vol. 15 (14), 4612-4621
- https://doi.org/10.1158/1078-0432.ccr-08-3321
Abstract
Purpose: CD11c is an antigen receptor predominantly expressed on dendritic cells (DC), to which antigen targeting has been shown to induce robust antigen-specific immune responses. To facilitate targeted delivery of tumor antigens to DCs, we generated fusion proteins consisting of the extracellular domain of human HER or its rat homologue neu, fused to the single-chain fragment variable specific for CD11c (scFvCD11c-HER2/neu). Experimental Design: Induction of cellular and humoral immune responses and antitumoral activity of the fusion proteins admixed with DC-activating CpG oligonucleotides (scFvCD11c-HER2/neuCpG) were tested in transplantable HER2/neu-expressing murine tumor models and in transgenic BALB-neuT mice developing spontaneous neu-driven mammary carcinomas. Results: Vaccination of BALB/c mice with scFvCD11c-HER2CpG protected mice from subsequent challenge with HER2-positive, but not HER2-negative, murine breast tumor cells, accompanied by induction of strong HER2-specific T-cell and antibody responses. In a therapeutic setting, injection of scFvCD11c-HER2CpG caused rejection of established HER2-positive tumors. Importantly, antitumoral activity of such a fusion protein vaccine could be reproduced in immunotolerant BALB-neuT mice, where scFvCD11c-neuCpG vaccination significantly protected against a subsequent challenge with neu-expressing murine breast tumor cells and markedly delayed the onset of spontaneous mammary carcinomas. Conclusions: CD11c-targeted protein vaccines for in vivo delivery of tumor antigens to DCs induce potent immune responses and antitumoral activities and provide a rationale for further development of this approach for cancer immunotherapy.Other Versions
This publication has 48 references indexed in Scilit:
- DNA Vaccines Targeting Tumor Antigens to B7 Molecules on Antigen-Presenting Cells Induce Protective Antitumor Immunity and Delay Onset of HER-2/Neu-Driven Mammary CarcinomaClinical Cancer Research, 2008
- Cancer Immunotherapy UsingIn vitroGenetically Modified Targeted Dendritic CellsCancer Research, 2008
- Putative IKDCs are functionally and developmentally similar to natural killer cells, but not to dendritic cellsThe Journal of Experimental Medicine, 2007
- Dendritic-cell immunotherapy: from ex vivo loading to in vivo targetingNature Reviews Immunology, 2007
- Peptide Vaccine Given with a Toll-Like Receptor Agonist Is Effective for the Treatment and Prevention of Spontaneous Breast TumorsCancer Research, 2007
- Receptor-Mediated Delivery of Antigens to Dendritic Cells: Anticancer ApplicationsMolecular Pharmaceutics, 2007
- Differential Antigen Processing by Dendritic Cell Subsets in VivoScience, 2007
- Immunosurveillance ofErbb2Carcinogenesis in Transgenic Mice Is Concealed by a Dominant Regulatory T-Cell Self-ToleranceCancer Research, 2006
- Effective induction of naive and recall T-cell responses by targeting antigen to human dendritic cells via a humanized anti–DC-SIGN antibodyBlood, 2005
- Adjuvant-free IgG responses induced with antigen coupled to antibodies against class II MHCNature, 1987